Women’s Health Takeaways for Primary Care: Expert Insights from ACOG 2025

At RAD 2025, Johann Gudjonsson, MD, PhD, discussed the OX-40 pathway’s role in AD, genetic links to disease risk, and promising combination therapies in development.

At ACOG 2025, Elizabeth Mollard, PhD, discussed her research on Medicaid PPD screening and coverage policies on PPD diagnosis.

From primary care management of heavy menstrual bleeding to postpartum depression screening, find out what you may have missed at ACOG 2025.

“I think it’s important to have a lot of tools in our toolbox, and [tapinarof cream 1%] is one that gives us great flexibility," said Linda Stein Gold, MD.

RAD 2025: Many adults achieved optimal treatment targets with upadacitinib after 6 months, regardless of prior biologic therapy, according to new late-breaking data.

RAD 2025: World expert on the pathophysiology of itch Gil Yosipovitch, MD, answers questions on the disease of chronic itch and on the expanding options for targeted treatment.